BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29988099)

  • 1. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
    Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
    O'Farrell S; Sandström K; Garmo H; Stattin P; Holmberg L; Adolfsson J; Van Hemelrijck M
    BJU Int; 2016 Sep; 118(3):391-8. PubMed ID: 26497726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
    Meng F; Zhu S; Zhao J; Vados L; Wang L; Zhao Y; Zhao D; Niu Y
    BMC Cancer; 2016 Mar; 16():180. PubMed ID: 26940836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
    Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
    Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
    Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients.
    Lu YC; Huang CY; Yeh HM; Hong JH; Chang CH; Muo CH; Chung SD; Yang TK; Jaw FS; Chung CJ
    Sci Rep; 2019 Oct; 9(1):14231. PubMed ID: 31578427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
    Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
    PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
    Liu R; Zhou J; Xia S; Li T
    Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.
    Wang H; Sun X; Zhao L; Chen X; Zhao J
    J Diabetes Investig; 2016 Jul; 7(4):629-36. PubMed ID: 27181717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
    Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
    Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
    Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
    Schmid M; Sammon JD; Reznor G; Kapoor V; Speed JM; Abdollah FA; Sood A; Chun FK; Kibel AS; Menon M; Fisch M; Sun M; Trinh QD
    BJU Int; 2016 Aug; 118(2):221-9. PubMed ID: 26074405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.